Last reviewed · How we verify

lopinavir with ritonavir in 1:1 ratio — Competitive Intelligence Brief

lopinavir with ritonavir in 1:1 ratio (lopinavir with ritonavir in 1:1 ratio) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

lopinavir with ritonavir in 1:1 ratio (lopinavir with ritonavir in 1:1 ratio) — Drugs for Neglected Diseases. Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
lopinavir with ritonavir in 1:1 ratio TARGET lopinavir with ritonavir in 1:1 ratio Drugs for Neglected Diseases marketed HIV protease inhibitor HIV protease
LPV/r LPV/r The HIV Netherlands Australia Thailand Research Collaboration marketed Protease inhibitor (PI) combination HIV protease
Fosamprenavir/ritonavir Fosamprenavir/ritonavir ViiV Healthcare marketed HIV protease inhibitor HIV protease
Combivir+Kaletra Combivir+Kaletra Hospital Clinic of Barcelona marketed Antiretroviral combination therapy (NRTI + protease inhibitor) HIV reverse transcriptase and HIV protease
Symtuza® (TAF/FTC/DRV/c) Symtuza® (TAF/FTC/DRV/c) Fundacion SEIMC-GESIDA marketed Antiretroviral combination (NRTI/INSTI class with protease inhibitor) HIV reverse transcriptase, HIV protease, CYP3A4
HIV therapy HIV therapy ViiV Healthcare marketed Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)
continue on current dual boosted PI continue on current dual boosted PI Community Research Initiative of New England marketed Protease inhibitor (PI) combination with pharmacokinetic booster HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

  1. Bristol-Myers Squibb · 5 drugs in this class
  2. ViiV Healthcare · 3 drugs in this class
  3. GlaxoSmithKline · 2 drugs in this class
  4. Drugs for Neglected Diseases · 2 drugs in this class
  5. Germans Trias i Pujol Hospital · 2 drugs in this class
  6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
  9. Far East Bio-Tec Co., Ltd · 1 drug in this class
  10. Community Research Initiative of New England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lopinavir with ritonavir in 1:1 ratio — Competitive Intelligence Brief. https://druglandscape.com/ci/lopinavir-with-ritonavir-in-1-1-ratio. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: